2017 Fiscal Year Final Research Report
Novel treatment for metastatic bone tumors
| Project/Area Number |
16K20042
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
Miwa Shinji 名古屋市立大学, 大学院医学研究科, 助教 (40753455)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | 骨転移 / GSK-3β / 前立腺癌 |
|---|
| Outline of Final Research Achievements |
The human prostate cancer PC-3 cells were genetically engineered to express RFP using a retrovirus. The cells were treated with SB216763 or AR-A014418 and evaluated by clonogenic assay. In the in vitro study, GSK-3β inhibitor inhibited proliferation of PC-3-RFP cells in a dose-dependent manner. PC-3-RFP cells in Matrigel were injected into the intramedullary cavity of the left tibia. One week after intratibial injection of cancer cells, the mice were treated by SB216763 or AR-A014418. GSK-3β inhibitors significantly reduced the fluorescent area of the tumor, tumor volume, and tumor weight.
|
| Free Research Field |
腫瘍
|
